An Environmental Scan of Consumer-Initiated Germline Genetic Testing for Health Risks.
Hannah G Kirby et al. Mayo Clin Proc 2023 8
From the abstract: "An environmental scan was conducted to identify germline genetic testing companies that offer testing for at least one diagnosable health condition and are available for purchase by consumers in the US market without a visit to one's health care provider. We characterized variability in the content and processes used by 21 companies offering 74 distinct test products that met our inclusion and exclusion criteria. A minority (8 of 21 companies) offered tests that assessed the presence of at least 1 US Centers for Disease Control and Prevention Tier 1 condition for which detection can impact an individual's clinical care and for which evidence-based guidelines for detection and management exist."
Curious about your cancer risk, or if your child might develop learning disabilities? There’s a genetic test for that—but it may not be accurate
E Prater, Fortune Well, July 2023
A new wave of expanded genetics tests is flooding the market—social media feeds, at least—and complicating matters. Some promise to predict the gender of your baby, your child’s predisposition to learning disabilities, how specific medications might interact with your genetics, and even how prone you are to developing ear wax. Not all information provided by such tests is useful or accurate. And not all of the accurate information can be acted upon, experts caution. Often, disease can’t be prevented.
Regulating Direct-to-Consumer Polygenic Risk Scores
JS Sherkow et al, JAMA, August 3, 2023
PGSs are available to consumers both through typical direct-to-consumer (DTC) genetic tests, where the consumer provides a genetic sample to be sequenced and analyzed by a company or as pure software, where consumers upload their previously sequenced genetic data to be analyzed. Although the US Food and Drug Administration (FDA) actively regulates DTCs, many DTC-PGSs evade regulatory scrutiny as general wellness products or unregulated software over which the FDA declines to exercise enforcement.
Assessing the general public's view of direct-to-consumer (DTC) genetic testing and their interpretation of DTC website disclaimer messages.
Madison Ruehl et al. Eur J Hum Genet 2023 6
The general public continues to show increased interest and uptake of Direct-to-Consumer (DTC) genetic testing. We conducted an online survey (N?=?405) to assess genetics knowledge, interest, and outcome expectancy of DTC genetic testing before and after exposure to a sample DTC disclaimer message.
Increased genetic knowledge and more positive attitudes towards DTC genetic testing were associated with increased self-reported systematic processing of the DTC disclaimer message. Further, self-reported systematic processing of the DTC disclaimer message was associated with greater interest in pursuing DTC genetic testing but did not predict outcome expectancies.